Demis Hassabis, chief of DeepMind spinout Isomorphic Labs, believes the company would halve drug discovery times after inking deals with Eli Lilly and Novartis (Financial Times) 10-01-2024
Financial Times: Demis Hassabis, chief of DeepMind spinout Isomorphic Labs, believes the company would halve drug discovery times after inking deals with Eli Lilly and Novartis — Chief of Google’s AI unit and Isomorphic Labs spells out targets following $3bn Eli Lilly-Novartis partnerships Lees verder op Tech Meme